Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Pediatr Endocrinol Metab ; 37(1): 21-26, 2024 Jan 29.
Article in English | MEDLINE | ID: mdl-37966142

ABSTRACT

OBJECTIVES: This study was conducted to study the expression of both microRNA-29a and microRNA-122, and serum levels of sestrin-2, interleukin-6 (IL-6), and other inflammatory markers among obese children with/and without diabetes mellitus. METHODS: One hundred obese children with diabetes in addition to 100 age- and sex-matched obese children without diabetes, and 100 age- and sex-matched apparently healthy children were included in the study. Expressions of both microRNA-29a and microRNA-122, and serum levels of sestrin-2, IL-6, tumor necrosis factor-α (TNF-α), and high sensitive-CRP (hsCRP) were measured for all included study populations. RESULTS: Study results showed that the expressions of both microRNA-29a and microRNA-122, serum levels of IL-6, TNF-α, and hsCRP were significantly higher among obese children with diabetes in comparison to both obese children without diabetes and healthy children. In contrast, serum sestrin level was significantly low among obese children with diabetes in comparison to the other study populations. Expressions of both microRNA-29a and microRNA-122 were correlated with waist circumference, BMI, total cholesterol, triglycerides, LDL-cholesterol, HbA1c, c-peptide, glucose, insulin, homeostatic model assessment-insulin resistance (HOMA-IR), IL-6, hsCRP, and TNF-α among obese children with diabetes. However, serum sestrin-2 level was correlated inversely with these parameters. Higher expressions of both microRNA-29a and microRNA-122 among obese children either with or without diabetes mellitus (DM) can suggest their roles in the development of obesity among children. CONCLUSIONS: The study results can hypothesize that down-regulation of these micro-RNAs may solve this health problem with its sequelae, a hypothesis that needs more studies.


Subject(s)
Diabetes Mellitus , Insulin Resistance , MicroRNAs , Pediatric Obesity , Child , Humans , Blood Glucose , Body Mass Index , C-Reactive Protein/metabolism , Cholesterol , Interleukin-6 , MicroRNAs/genetics , Pediatric Obesity/complications , Pediatric Obesity/genetics , Sestrins , Tumor Necrosis Factor-alpha
2.
Diabetes Metab Res Rev ; 36(5): e3299, 2020 07.
Article in English | MEDLINE | ID: mdl-32043290

ABSTRACT

BACKGROUND AND OBJECTIVE: Diabetic nephropathy (DN) is the most common cause of end stage renal failure or even death among patients with type 2 diabetes mellitus. Genetic predisposition is widely studied among these patients to identify manageable aspects of the disease pathogenesis. This study was carried out to test the association of engulfment and cell motility 1 (ELMO1) gene polymorphism with DN among Egyptians. ELMO1 is required for phagocytosis of apoptotic cells and cell motility. METHODS: This case-control study was conducted on type 2 diabetic patients who attended Suez Canal University Hospital, Egypt, between November 2016 and October 2017. Peripheral blood was collected from 200 diabetic patients (without nephropathy), 200 patients with DN, and 100 healthy controls for DNA extraction. The single nucleotide polymorphism of ELMO1 (rs741301) was genotyped using real-time polymerase chain reaction and the allele discrimination technique. RESULTS: GG genotype was significantly associated with DN (odds ratio [OR] = 2.7; 95% confidence interval [CI]: 1.4-5.3) (P = .016). The OR for the high-risk allele (G) was 1.9 with 95% CI from 1.5 to 2.9 (P < .001). CONCLUSION: ELMO1 gene (rs741301) polymorphism is a candidate variant in the predisposition to DN.


Subject(s)
Adaptor Proteins, Signal Transducing/genetics , Biomarkers/analysis , Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/etiology , Genetic Predisposition to Disease , Polymorphism, Single Nucleotide , Blood Glucose/analysis , Diabetic Nephropathies/epidemiology , Diabetic Nephropathies/pathology , Egypt/epidemiology , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prognosis
3.
Diabetes Metab Syndr ; 12(5): 711-714, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29699951

ABSTRACT

BACKGROUND: Metabolic syndrome (MS) is considered one of the major worldwide epidemics. It accounts for billions of cardiovascular disease events and deaths. Till now, major basics of MS are not fully clarified. Peroxisome Proliferator-Activated Receptor-α (PPARα) displays a ligand-activated transcription factor. It is involved in the regulation of many metabolic processes including inflammation, lipid, and glucose metabolism. Therefore, this study investigated the leucocytic expression of PPARα in a metabolic patient in comparison to healthy controls. METHODS: 100 subjects with MS were recruited, in addition to 100 subjects without any obvious metabolic disorders as healthy controls. Expression of PPARα and CD 36 were analyzed on different leucocytic populations using optimized flow-cytometric analysis. Correlations of the expression of both indexes with different clinical and laboratory parameters were analyzed. RESULTS: The eosinophilic expression of PPARα was found to be lower in subjects with MS in comparison to the healthy controls (p value 0.001). Also, PPARα expression, on most of the leucocytic populations, was inversely correlated with waist circumferences among the study populations. CONCLUSION: Circulated eosinophilic expression of PPARα protein is reduced in MS subjects. This conclusion may explain the endothelial dysfunction and obesity associated with MS, as well as it may help in the management of this worldwide health problem.


Subject(s)
Eosinophils/metabolism , Leukocytes, Mononuclear/metabolism , Metabolic Syndrome/blood , Metabolic Syndrome/diagnosis , PPAR alpha/biosynthesis , PPAR alpha/blood , Adult , Case-Control Studies , Egypt/epidemiology , Female , Gene Expression Regulation , Humans , Male , Metabolic Syndrome/epidemiology , Middle Aged , PPAR alpha/genetics
4.
Clin Exp Hypertens ; 39(8): 764-768, 2017.
Article in English | MEDLINE | ID: mdl-28686109

ABSTRACT

This study was conducted to test the association between promoter DNA methylation of α-Adducin (ADD1) gene and the risk of essential hypertension (EH). A total of 150 EH patients and 100 aged- and gender-matched controls were investigated. DNA methylation levels of five cytosine-phosphate-guanine (CpG) dinucleotides on ADD1 promoter were measured employing bisulfite pyrosequencing technology. Our results showed that females have a higher ADD1 DNA methylation than males and a significantly lower CpG1 methylation level is associated with increased risk of EH among them. As for males, a significant association between lower CpG2-5 methylation levels and increased risk of EH was shown. In addition, CpG2-5 methylation was found to be a highly significant predictor for EH among males. In females, CpG1 methylation was considered a predictor of hypertension. No significant correlations were found with biochemical measures, apart from the concentration of aspartate aminotransferase which was inversely correlated with ADD1 CpG2-5 methylation levels among female controls (r = -0.703). These findings highlight that ADD1 methylation may have a contributing role in the pathogenesis of EH with varying implications for both genders.


Subject(s)
Calmodulin-Binding Proteins/genetics , DNA Methylation , Essential Hypertension/genetics , Aspartate Aminotransferases/blood , Case-Control Studies , CpG Islands/genetics , Essential Hypertension/blood , Female , Humans , Hypertension/physiopathology , Male , Middle Aged , Promoter Regions, Genetic , Risk Factors , Sex Factors
5.
Saudi Med J ; 33(5): 489-94, 2012 May.
Article in English | MEDLINE | ID: mdl-22588808

ABSTRACT

OBJECTIVE: To investigate the relationship between cluster of differentiation (CD)36 gene variant rs1761667 (G>A) and metabolic syndrome (MetS) and its components in Egyptian patients. METHODS: This case-control study was conducted on MetS patients attending Suez Canal University Hospital, Egypt from November 2010 to October 2011. Peripheral blood was collected from 100 patients and 100 healthy controls for DNA extraction. The single nucleotide polymorphism (SNP) CD36 gene rs1761667 (G>A) was genotyped using real-time polymerase chain reaction, and allele discrimination technique. RESULTS: Distribution of CD36 genotypes in the patient group was AA (n=25), AG (n=70), and GG (n=5) while in the control group it was AA (n=51), AG (n=48), and GG (n=1). Both AG and GG genotypes were significantly more prevalent among MetS patients (p<0.001). The odds ratio (OR) for the high risk allele (G) is 2 with 95% confidence interval from 1.30-3.07 (p<0.001). Patients with genotypes AG and GG had significantly higher systolic blood pressure, wider waist circumstance, and higher degree of dyslipidemia (p<0.001) than patients with genotype AA. CONCLUSION: Our findings show that CD36 rs1761667 SNP is positively associated with increased risk of MetS and its components with genotype AG heterozygotes showing highest frequency among MetS patients.


Subject(s)
CD36 Antigens/genetics , Genetic Predisposition to Disease/epidemiology , Genetic Variation , Metabolic Syndrome/genetics , Adult , Age Distribution , Alleles , Case-Control Studies , Cluster Analysis , Confidence Intervals , Egypt/epidemiology , Female , Genotype , Humans , Incidence , Male , Metabolic Syndrome/epidemiology , Middle Aged , Odds Ratio , Polymorphism, Single Nucleotide , Real-Time Polymerase Chain Reaction , Reference Values , Sex Distribution
SELECTION OF CITATIONS
SEARCH DETAIL
...